FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Teva to sell assets to reduce debt, lay-off 7,000 workers; Shkreli awaits sentence
This week in Phispers, we look at the growing troubles at Teva. The company plans to divest non-core